Search Results
Found 1 results
510(k) Data Aggregation
(99 days)
PREMIER PLATINUM HPSA PLUS, MODELS 601396, 601480
The Premier Platinum HpSA PLUS enzyme immunoassay (EIA) is an in vitro qualitative procedure for the detection of Helicobacter pylori antigens in human stool. Test results are intended to aid in the diagnosis of H. pylori infection and to monitor response during and post-therapy in patients. Accepted medical practice recommends that testing by any current method, to confirm eradication, be done at least four weeks following completion of therapy.
Premier Platinum HpSA PLUS is an in vitro diagnostic, microwell-based, enzymelinked immunoassay for the detection of Helicobacter pylori antigen in human stool. The assay is intended for use in clinical laboratories to test for bacterial colonization to aid diagnosis, or monitor a patient's response during therapy to eradicate infection. The assay consists of Microwells coated with specific antibodies (solid phase/capture antibodies), Enzyme Conjugate (detector antibodies), Sample Diluent, Premier 20X Wash Buffer I, Premier Substrate Solution I, Premier Stop Solution I and Positive Control. Sample Diluent also functions as the Negative Control reagent.
No calibrators are needed to use this device.
Here's an analysis of the provided text regarding the acceptance criteria and study for the Premier Platinum HpSA PLUS device:
Device Acceptance Criteria and Performance Study Analysis
The submission describes the Premier Platinum HpSA PLUS, an in vitro diagnostic enzyme immunoassay (EIA) for detecting H. pylori antigen in human stool. The primary goal of the submission is to demonstrate substantial equivalence to a predicate device, Premier Platinum HpSA.
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria are not explicitly stated as a separate section with predefined targets. Instead, the study aims to demonstrate that the new device performs "similarly" to the predicate, and that certain analytical performance characteristics are met. Based on the provided text, I've inferred the acceptance criteria from the reported performance and the comparisons made to the predicate or industry standards like EP12-A.
Acceptance Criteria (Implied/Direct) | Reported Device Performance (Premier Platinum HpSA PLUS) |
---|---|
Clinical Performance (vs. Predicate) | |
Overall Agreement with Predicate | 96.5% |
Positive Agreement with Predicate | 100% |
Negative Agreement with Predicate | 94.8% |
Improvement over Predicate for Indeterminate Results | Clarified 7 out of 7 indeterminate results from predicate as definite positive using other tests (CLO/Histology/UBT) by HpSA PLUS, and 1 indeterminate result as definite negative. |
Analytical Performance | |
Precision/Reproducibility (intra-assay) | 97% (compared to predicate's 100% – this is for intra-assay, not overall reproducibility which is stated as 100%) |
Overall Reproducibility | 100% (for samples above or below the limit of analytical sensitivity) |
Performance of "High negative" samples at cutoff | Produced weakly positive results 42 out of 162 times (expected ~50% based on EP12-A) |
Limit of Detection (H. pylori flagellar antigen in stool) | ≥ 4.67 ng/mL |
Limit of Detection (H. pylori bacterial strain in stool) | ≥ 1.0 % organisms/mL (assuming the missing exponent is 10^?) |
Assay Cutoff | 0.100 at OD450/630 |
Absence of Indeterminate Range | All results definitive (no 0.100-0.120 OD range needed, unlike predicate) |
Absence of Interference from Drugs/Nonmicrobial Substances | None had a significant effect on negative test results; positive results correlated closely with unspiked samples. |
Absence of Interference from Microbial/Viral Organisms | None adversely affected final positive or negative test results. |
Therapeutic Monitoring Performance | Eradication curves were substantively the same as predicate for strongly positive samples; differed at low positive states initially but identical by week four post-treatment. |
2. Sample Size Used for the Test Set and the Data Provenance
- Test Set (Clinical Comparison): 291 samples from symptomatic patients.
- Data Provenance: Not explicitly stated, but collected from "symptomatic patients" suggesting a clinical setting. It is retrospective as 33 of these samples were originally evaluated in an earlier trial for the predicate device.
- Test Set (Reproducibility): 2 high positive, 2 low negative, 1 low positive, and 1 high negative specimen in a reference panel, with 9 replicates each of the low positive and high negative samples, bringing the total cohort to 22 reference specimens.
- Data Provenance: Prepared from "archival specimens" and tested in "three different laboratories." This indicates a controlled, retrospective, and multi-site analytical study.
- Test Set (Interference Testing): 5 known H. pylori-positive and 5 known negative samples for drug interference; an unspecified number of samples for microbial/viral interference.
- Data Provenance: Laboratory-controlled spike-in experiments, prospective in nature for the study itself, using known positive/negative samples.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and the Qualifications of Those Experts
There were no experts used to establish ground truth in the traditional sense for the clinical comparison. Instead, "other conventional tests such as CLO, Histology, or UBT" were used to arbitrate discordant results between the new device and the predicate. The qualifications of those performing these conventional tests are not specified.
4. Adjudication Method for the Test Set
For the clinical comparison, when results between Premier Platinum HpSA PLUS and the predicate were discordant, they were adjudicated against "test data from other conventional tests such as CLO, Histology, or UBT to determine the trueness of the results." This implies a form of external reference standard adjudication, rather than a consensus among human readers of the device output. It's not a 2+1 or 3+1 method directly related to human interpretation of the device results, but rather a comparison to established diagnostic methods.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, If So, What Was the Effect Size of How Much Human Readers Improve with AI vs. Without AI Assistance
No MRMC study was done, nor is this an AI/human-in-the-loop device. It is a laboratory-based enzyme immunoassay. The comparison is between two similar lab tests.
6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) Was Done
Yes, this is a standalone device. Its performance characteristics are reported as the output of the assay itself, interpreted quantitatively (OD readings) against a predefined cutoff. There is no human interpretation component in the sense of a radiologist reading an image or a pathologist reviewing a slide that would then be assisted by AI.
7. The Type of Ground Truth Used
- Clinical Comparison (for discordant results): A combination of other conventional diagnostic tests for H. pylori infection (CLO, Histology, UBT). These serve as the de facto "ground truth" to determine if the device's results are true positives/negatives.
- Analytical Sensitivity (Limit of Detection): Purified antigens and bacterial strains, where known concentrations were spiked, serving as a controlled, known standard.
- Interference Testing: Known H. pylori-positive and negative samples spiked with various substances/microbes, representing a known state (positive/negative for H. pylori, plus presence of interferent).
- Reproducibility: A reference panel with defined states (high positive, low positive, high negative, low negative), serving as a known standard.
8. The Sample Size for the Training Set
No specific training set is mentioned as this device is not an AI/machine learning algorithm that requires a training phase. It is a traditional immunoassay.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as there is no training set for this type of device.
Ask a specific question about this device
Page 1 of 1